Severe Ectropion in Harlequin Ichthyosis Managed Nonsurgical: Case Report

Authors

  • João Vaz Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal https://orcid.org/0000-0002-4518-3854
  • Mariana Vaz Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal
  • Ana Cardoso Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal
  • Audrey Sampaio Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal
  • Nuno Campos Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal
  • Ana Vide-Escada Integrated Responsibility Center of Ophthalmology, Unidade Local de Saúde Almada-Seixal, Almada, Portugal

DOI:

https://doi.org/10.48560/rspo.43745

Keywords:

Corneal Diseases/etiology, Corneal Diseases/therapy, Ectropion/etiology, Ectropion/therapy, Ichthyosis, Lamellar/therapy, Infant

Abstract

Harlequin ichthyosis (HI) is the most severe form of autosomal recessive congenital ichthyosis, caused by pathogenic variants in ABCA12. Ocular manifestations, particularly cicatrical ectropion and exposure keratopathy, may threaten corneal integrity. Reports detailing successful nonsurgical ophthalmic management remain scarce.

A full-term female neonate presented at birth with generalized hyperkeratosis, skin fissuring, severe bilateral ectropion, and superficial punctate keratopathy. Genetic testing confirmed biallelic ABCA12 variants. Systemic acitretin therapy was initiated, complemented by topical tazarotene and emollients. Ocular management consisted of daily eyelid massage, protective moisture chambers, preservative-free artificial tears, and vitamin A-based ointment.

Progressive regression of ectropion and complete resolution of keratopathy were observed. At 18 months, the patient showed a stable skin condition, clear corneas, and normal visual development, without surgical intervention.

Early multidisciplinary medical management can effectively stabilize ocular and systemic manifestations of HI, avoiding high-risk reconstructive surgery and preserving long-term visual outcomes.

Downloads

Download data is not yet available.

References

Rathore S. Harlequin ichthyosis: prenatal diagnosis of a rare yet severe genetic dermatosis. J Clin Diagn Res. 2015;9:QD04-6. doi:10.7860/JCDR/2015/15250.6705

Akiyama M. The roles of ABCA12 in keratinocyte differentiation and lipid barrier formation in the epidermis. Dermatoendocrinology. 2011;3:107-12. doi:10.4161/derm.3.2.15136

Vahlquist A, Fischer J, Torma H. Inherited nonsyndromic ichthyoses: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2018;19:51-66. doi:10.1007/s40257-017-0313-x

Glick JB, Craiglow BG, Choate KA, Kato H, Fleming RE, Siegfried EC, et al. Improved management of harlequin ichthyosis with advances in neonatal intensive care. Pediatrics. 2017;139:e20161003. doi:10.1542/peds.2016-1003

Al-Amry MA. Ocular manifestations of ichthyosis. Saudi J Ophthalmol. 2016;30:39-43. doi:10.1016/j.sjopt.2015.12.004

Yeoh BJ, Nanthini S. Ophthalmic review on neonatal harlequin ichthyosis. Cureus. 2023;15:e44320. doi:10.7759/cureus.44320

Downloads

Published

2026-06-13

How to Cite

Vaz, J., Vaz, M., Cardoso, A., Sampaio, A., Campos, N., & Vide-Escada, A. (2026). Severe Ectropion in Harlequin Ichthyosis Managed Nonsurgical: Case Report. Revista Sociedade Portuguesa De Oftalmologia, 50(2), 168–171. https://doi.org/10.48560/rspo.43745

Issue

Section

Case Reports